KR20220143164A - 치환된 리버스 피리미딘 ｂｍｉ-1 저해제 - Google Patents

치환된 리버스 피리미딘 ｂｍｉ-1 저해제 Download PDF

Info

Publication number
KR20220143164A
KR20220143164A KR1020227035587A KR20227035587A KR20220143164A KR 20220143164 A KR20220143164 A KR 20220143164A KR 1020227035587 A KR1020227035587 A KR 1020227035587A KR 20227035587 A KR20227035587 A KR 20227035587A KR 20220143164 A KR20220143164 A KR 20220143164A
Authority
KR
South Korea
Prior art keywords
diamine
fluoro
pyrimidine
benzimidazol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227035587A
Other languages
English (en)
Korean (ko)
Inventor
창선 이
라밀 바이아지토브
리앙시안 카오
토마스 더블유. 데이비스
우 두
롱강 리우
영춘 문
스티븐 디. 페이젯
홍유 렌
나디야 시도렌코
리처드 제랄드 와일드
Original Assignee
피티씨 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피티씨 테라퓨틱스, 인크. filed Critical 피티씨 테라퓨틱스, 인크.
Publication of KR20220143164A publication Critical patent/KR20220143164A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
KR1020227035587A 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제 Ceased KR20220143164A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21
US61/728,907 2012-11-21
KR1020227002513A KR102455889B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
PCT/US2013/071132 WO2014081906A2 (en) 2012-11-21 2013-11-21 Substituted reverse pyrimidine bmi-1 inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002513A Division KR102455889B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제

Publications (1)

Publication Number Publication Date
KR20220143164A true KR20220143164A (ko) 2022-10-24

Family

ID=50776672

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227035587A Ceased KR20220143164A (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020157016184A Active KR102275676B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020217020963A Active KR102356487B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020227002513A Active KR102455889B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020157016184A Active KR102275676B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020217020963A Active KR102356487B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020227002513A Active KR102455889B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제

Country Status (32)

Country Link
US (3) US10428050B2 (Direct)
EP (1) EP2922828B1 (Direct)
JP (3) JP6412503B2 (Direct)
KR (4) KR20220143164A (Direct)
CN (2) CN104918919A (Direct)
AR (1) AR093579A1 (Direct)
AU (1) AU2013348009C1 (Direct)
BR (1) BR112015011760B1 (Direct)
CA (1) CA2892045C (Direct)
CL (1) CL2015001377A1 (Direct)
CR (1) CR20150294A (Direct)
CU (1) CU24387B1 (Direct)
DK (1) DK2922828T3 (Direct)
EA (2) EA035349B1 (Direct)
EC (1) ECSP15019948A (Direct)
ES (1) ES2821529T3 (Direct)
HK (1) HK1215032A1 (Direct)
IL (2) IL238871B (Direct)
MA (1) MA38208B1 (Direct)
MX (2) MX385385B (Direct)
NI (1) NI201500072A (Direct)
NZ (2) NZ746607A (Direct)
PE (1) PE20151413A1 (Direct)
PH (1) PH12015501130B1 (Direct)
PL (1) PL2922828T3 (Direct)
PT (1) PT2922828T (Direct)
SA (1) SA517381847B1 (Direct)
SG (2) SG10201600149VA (Direct)
TW (1) TWI623531B (Direct)
UA (1) UA118094C2 (Direct)
WO (1) WO2014081906A2 (Direct)
ZA (1) ZA201503642B (Direct)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201600149VA (en) * 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10376510B2 (en) * 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
WO2015030847A1 (en) * 2013-08-30 2015-03-05 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
US10874355B2 (en) 2014-04-24 2020-12-29 Cognoa, Inc. Methods and apparatus to determine developmental progress with artificial intelligence and user input
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
EP3402780A1 (en) * 2016-01-14 2018-11-21 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
JP7182554B2 (ja) 2016-11-14 2022-12-02 コグノア，インク． 発達に係る疾病を評価し、およびカバー率と信頼度に対する制御を提供する方法および装置
WO2018148365A1 (en) * 2017-02-09 2018-08-16 Cognoa, Inc. Platform and system for digital personalized medicine
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
CA3109386A1 (en) * 2018-08-17 2020-03-19 Ptc Therapeutics, Inc. Use of 5-fluoro-2-(6-fluoro-2-methyl-1h-benzo(d)imidazol-1-yl)-n4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine in the treatment of pancreatic cancer
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
AU2020209767B2 (en) * 2019-01-15 2025-03-06 Ptc Therapeutics, Inc. Method for treating an acute myeloid leukemia
CN113710670A (zh) * 2019-02-28 2021-11-26 Ptc医疗公司 治疗多发性骨髓瘤的方法
JP2022524424A (ja) * 2019-03-11 2022-05-02 ピーティーシー セラピューティクス， インコーポレイテッド 向上したバイオアベイラビリティを有する化合物形態及びその製剤
CN113873935B (zh) 2019-03-22 2024-11-22 科格诺亚公司 个性化数字化治疗方法和装置
EA202192349A1 (ru) * 2019-03-27 2022-02-01 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Комбинации, пригодные в способе лечения саркомы
CA3135929A1 (en) * 2019-04-02 2020-10-08 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (Direct) * 1973-09-20 1977-11-30 Delalande Sa
DE69530989T2 (de) 1994-08-13 2004-05-19 Yuhan Corp. Neue pyrimidinderivate und verfahren zu ihrer herstellung
IN188411B (Direct) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
CA2386218A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
AU7922900A (en) 1999-10-27 2001-05-08 Novartis Ag Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
HUP0300382A3 (en) 2000-03-29 2006-11-28 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
CA2422367C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2423050A1 (en) 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
JP2004515550A (ja) 2000-12-15 2004-05-27 グラクソ グループ リミテッド 治療用化合物
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
ES2316546T3 (es) 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
CA2439263C (en) * 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
CA2452603A1 (en) 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003075828A2 (en) * 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
ATE457025T1 (de) 2002-05-23 2010-02-15 Cytopia Res Pty Ltd Kinaseinhibitoren
ATE447560T1 (de) 2002-06-28 2009-11-15 Nippon Shinyaku Co Ltd Amidderivat
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (en) 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
US7582630B2 (en) 2002-10-15 2009-09-01 Smithkline Beecham Corporation Pyradazine compounds as GSK-3 inhibitors
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
BRPI0506817A (pt) 2004-01-12 2007-05-29 Cytopia Res Pty Ltd inibidores seletivos de quinase
JP2007520558A (ja) 2004-02-04 2007-07-26 スミスクライン・ビーチャム・コーポレイション キナーゼ阻害剤として有用なピリミジノン化合物
EP2332940B1 (en) * 2004-03-30 2012-10-31 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
EP1854793A4 (en) 2005-02-28 2011-01-26 Japan Tobacco Inc NEW AMINOPYRIDEIN COMPOUND WITH SYK-HEMDERING EFFECT
PE20061067A1 (es) 2005-03-10 2006-11-30 Bayer Pharmaceuticals Corp Derivados de pirimidina
BRPI0713328A2 (pt) 2006-06-22 2012-10-30 Biovitrum Ab derivados de piridina e pirazina como inibidores de cinase mnk
MX2009003142A (es) 2006-10-03 2009-04-06 Neurosearch As Derivados de indazolilo utiles como agentes moduladores del canal de potasio.
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
BRPI0717773A2 (pt) * 2006-10-19 2013-11-05 Signal Pharm Llc Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula que expressa a dita quinase
JP2010514689A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物
AR065015A1 (es) 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
TW200846344A (en) 2007-04-25 2008-12-01 Astrazeneca Ab Chemical compounds
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
US8415358B2 (en) 2007-09-17 2013-04-09 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
KR101580482B1 (ko) 2007-11-16 2015-12-28 인사이트 홀딩스 코포레이션 야누스 키나제 억제제로서의 ４－피라졸릴－ｎ－아릴피리미딘－２－아민 및 ４－피라졸릴－ｎ－헤테로아릴피리미딘－２－아민
ES2374480T3 (es) 2007-12-07 2012-02-17 Novartis Ag Derivados pirazol y uso de los mismos como inhibidores de quinasas dependientes de ciclina.
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
WO2010002985A1 (en) * 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
WO2010026087A1 (en) * 2008-09-02 2010-03-11 Neurosearch A/S Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
WO2010061903A1 (ja) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
US20120165309A1 (en) 2009-02-12 2012-06-28 Astellas Pharma Inc. Hetero ring derivative
US8461158B2 (en) 2009-03-27 2013-06-11 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
MX2011012629A (es) 2009-05-27 2012-03-06 Abbott Lab Inhibidores de actividad de cinasa tipo pirimidina.
WO2010144416A1 (en) 2009-06-08 2010-12-16 Gaeta Federico C A SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
JP5721706B2 (ja) 2009-06-17 2015-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルス複製の阻害剤
ES2706185T3 (es) 2009-07-07 2019-03-27 Mei Pharma Inc Pirimidinil y 1,3,5-triazinil bencimidazoles y sus usos en la terapia contra el cáncer
CN102471345A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡嗪抑制剂
CA2767089A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
JP5734313B2 (ja) 2010-01-12 2015-06-17 アーべー・シオンス チアゾールおよびオキサゾールキナーゼ阻害剤
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
KR101788903B1 (ko) * 2010-08-19 2017-10-23 에프. 호프만-라 로슈 아게 체세포의 유도된 재프로그래밍된 신경 줄기 세포 (ｉｒｎｓｃｓ) 로의 전환
KR101843600B1 (ko) 2010-09-13 2018-03-29 노파르티스 아게 트리아진-옥사디아졸
WO2012050884A2 (en) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
EP2796456A1 (en) 2010-12-09 2014-10-29 Amgen Inc. Bicyclic compounds as Pim inhibitors
MX337477B (es) 2011-02-25 2016-03-07 Yuhan Corp Derivados de diaminopiridina y procesos para su preparacion.
EP2729459B1 (en) * 2011-07-07 2018-08-22 Merck Patent GmbH Substituted azaheterocycles for the treatment of cancer
SG10201600149VA (en) * 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
JP2022524424A (ja) * 2019-03-11 2022-05-02 ピーティーシー セラピューティクス， インコーポレイテッド 向上したバイオアベイラビリティを有する化合物形態及びその製剤

Non-Patent Citations (72)

* Cited by examiner, † Cited by third party
Title
A. A. Alizadeh et al., Nature 403, 503 (2000).
A. Dutton et al., Blood 109, 2597 (2007).
B. Quesnel, C. Preudhomme, P. Fenaux, Leuk. Lymphoma 22, 11 (1996).
B. Scheijen, J. Jonkers, D. Acton, A. Berns, J. Virol. 71, 9 (1997).
B. T. Spike, K. F. Macleod, Cell Cycle 4, 42 (2005).
Breuer et al., 2005, Lung Cancer. 48:299-306.
C. P. Hans et al., Blood 103, 275 (2004).
D. F. Dukers et al., Am. J. Pathol. 164, 873 (2004).
E. M. Hurt, B. T. Kawasaki, G. J. Klarmann, S. B. Thomas, W. L. Farrar, Br.J. Cancer 98, 756 (2008).
F. J. van Kemenade et al., Blood 97, 3896 (2001).
F. M. Raaphorst et al., Am. J. Pathol. 157, 709 (2000).
F. M. Raaphorst et al., Am. J. Pathol. 164, 533 (2004).
F. M. Raaphorst, C. J. Meijer, A. P. Otte, Cancer Res. 62, 618 (2002).
F. Zhang, L. Sui, T. Xin, Exp. Oncol. 30, 70 (2008).
G. D. van et al., Exp. Hematol. 35, 1538 (2007).
G. P. Dimri et al., Cancer Res. 62, 4736 (2002).
G. V. Glinsky, O. Berezovska, A. B. Glinskii, J. Clin. Invest 115, 1503-1521 (2005).
H. Cui et al., Am. J. Pathol. 170, 1370-1378 (2007).
H. Koga et al., Oncogene 18, 3799 (1999).
H. Vekony et al., J. Clin. Pathol. 61, 744 (2008).
H. Wang et al., J. Cancer Res. Clin. Oncol. 134, 535 (2008).
I. B. Engelsen et al., Br. J. Cancer 98, 1662 (2008).
J. B. Arnes, K. Collett, L. A. Akslen, Histopathology 52, 370 (2008).
J. C. van Galen et al., J. Clin. Pathol. 60, 167 (2007).
J. H. Kim et al., Breast 13, 383-388 (2004).
J. H. Kim et al., Cancer Lett. 203, 217 (2004).
J. H. Liu et al., J. Surg. Oncol. 97, 267 (2008).
J. J. Jacobs et al., Genes Dev. 13, 2678 (1999).
J. J. Jacobs, K. Kieboom, S. Marino, R. A. DePinho, L. M. van, Nature 397, 164 (1999).
J. M. Adams, S. Cory, Cancer Surv. 15, 119 (1992).
J. Wei, L. Zhai, J. Xu, H. Wang, J. Biol. Chem. 281, 22537 (2006).
J. Yang et al., Proc. Natl. Acad. Sci. U. S. A 104, 10494 (2007).
K. H. Huang, J. H. Liu, X. X. Li, L. B. Song, M. S. Zeng, Nan. Fang Yi. Ke. Da. Xue. Xue. Bao. 27, 973 (2007).
K. Mihara et al., Blood 107, 305 (2006).
K. Mihara et al., Rinsho Ketsueki 48, 659 (2007).
K. Nowak et al., Nucleic Acids Res. 34, 1745 (2006).
L. B. Song et al., Cancer Res. 66, 6225 (2006).
L. Liu, L. G. Andrews, T. O. Tollefsbol, Oncogene 25, 4370-4375 (2006).
L. M. van et al., Cell 65, 737 (1991).
L. M. van, M. Frasch, E. Wientjens, A. Berns, Nature 353, 353 (1991).
Lessard et al., 2003, Nature 423:255-260.
M. Chowdhury et al., Leukemia 21, 1116 (2007).
M. Courel, L. Friesenhahn, J. A. Lees, Dev. Dyn. 237, 1232 (2008).
M. J. Alkema, J. Wiegant, A. K. Raap, A. Berns, L. M. van, Hum. Mol. Genet. 2, 1597 (1993).
M. K. Kang et al., Br. J. Cancer 96, 126 (2007).
M. S. Lindstrom, U. Klangby, K. G. Wiman, Oncogene 20, 2171 (2001).
M. Sanchez-Beato et al., J. Pathol. 204, 528 (2004).
M. Sawa et al., Int. J. Hematol. 82, 42-47 (2005).
N. Kozakowski, A. Soleiman, J. Pammer, Pathol. Oncol. Res. 14, 9 (2008).
P. R. Solomon et al., Indian J. Med. Res. 127, 52 (2008).
Park et al., 2003, Nature. 423:302-305.
R. H. Breuer et al., Neoplasia. 6, 736 (2004).
R. Kuppers, U. Klein, M. L. Hansmann, K. Rajewsky, N. Engl. J. Med. 341, 1520 (1999).
Reinisch et al., 2006, Histol Histopathol. 21:1143-1149.
S. Bea et al., Blood 93, 4365 (1999).
S. Bea et al., Cancer Res. 61, 2409 (2001).
S. Faderl et al., Clin. Cancer Res. 5, 1855 (1999).
S. Faderl et al., Cytokines Cell Mol. Ther. 5, 159 (1999).
S. J. Kuerbitz, J. Malandro, N. Compitello, S. B. Baylin, J. R. Graff, Cell Growth Differ. 10, 27 (1999).
S. K. Li et al., J. Biol. Chem. (2008).
S. Liu et al., Cancer Res. 66, 6063 (2006).
S. Vonlanthen et al., Br. J. Cancer 84, 1372 (2001).
S. W. Bruggeman et al., Cancer Cell 12, 328 (2007).
V. Fernandez, E. Hartmann, G. Ott, E. Campo, A. Rosenwald, J. Clin. Oncol. 23, 6364 (2005).
V. Hayry et al., Acta Neuropathol. (2008).
V. Hayry et al., Neuropathol. Appl. Neurobiol. (2008).
W. A. Dik et al., Leukemia 19, 1948 (2005).
W. J. Guo, S. Datta, V. Band, G. P. Dimri, Mol. Biol. Cell 18, 536 (2007).
W. P. de Boer, J. J. Oudejans, C. J. Meijer, J. Lankelma, Bioinformatics. 19, 2000 (2003).
Wiederschain et al., 2007, Mol Cell Biol. 27(13):4968-4967.
Y. Haupt, G. Barri, J. M. Adams, Mol. Biol. Rep. 17, 17 (1992).
Y. Haupt, M. L. Bath, A. W. Harris, J. M. Adams, Oncogene 8, 3161-3164 (1993).

Also Published As

Publication number Publication date
CN104918919A (zh) 2015-09-16
MX2021009892A (es) 2021-09-14
US20150315182A1 (en) 2015-11-05
PL2922828T3 (pl) 2020-12-28
WO2014081906A3 (en) 2014-07-17
KR102356487B1 (ko) 2022-02-08
ZA201503642B (en) 2020-10-28
DK2922828T3 (da) 2020-08-31
NI201500072A (es) 2016-01-18
JP6412503B2 (ja) 2018-10-24
MX385385B (es) 2025-03-18
PH12015501130B1 (en) 2023-01-27
MA38208B1 (fr) 2021-12-31
ES2821529T3 (es) 2021-04-26
CN111423417B (zh) 2022-11-15
US11180483B2 (en) 2021-11-23
EP2922828A4 (en) 2016-07-27
CR20150294A (es) 2015-08-20
TW201427972A (zh) 2014-07-16
IL238871B (en) 2019-03-31
CA2892045C (en) 2022-05-31
CN111423417A (zh) 2020-07-17
SA517381847B1 (ar) 2021-07-17
WO2014081906A2 (en) 2014-05-30
KR102275676B1 (ko) 2021-07-12
US10428050B2 (en) 2019-10-01
PH12015501130A1 (en) 2015-08-03
CU20150053A7 (es) 2015-11-27
US20220064150A1 (en) 2022-03-03
EA201590992A1 (ru) 2015-11-30
BR112015011760A2 (pt) 2017-07-11
SG11201503982XA (en) 2015-06-29
AU2013348009C1 (en) 2019-08-08
AU2013348009A1 (en) 2015-06-04
AR093579A1 (es) 2015-06-10
JP2020055815A (ja) 2020-04-09
KR20210088740A (ko) 2021-07-14
NZ746607A (en) 2019-11-29
TWI623531B (zh) 2018-05-11
PT2922828T (pt) 2020-10-12
EA201890142A1 (ru) 2018-06-29
JP6918898B2 (ja) 2021-08-11
AU2013348009B2 (en) 2018-05-17
US20200024260A1 (en) 2020-01-23
NZ708909A (en) 2019-11-29
EA031405B1 (ru) 2018-12-28
EP2922828B1 (en) 2020-07-08
HK1215032A1 (zh) 2016-08-12
IL238871A0 (en) 2015-07-30
UA118094C2 (uk) 2018-11-26
MX2015006469A (es) 2015-10-29
PE20151413A1 (es) 2015-10-23
JP6617186B2 (ja) 2019-12-11
KR102455889B1 (ko) 2022-10-17
EA035349B1 (ru) 2020-05-29
KR20150086345A (ko) 2015-07-27
BR112015011760B1 (pt) 2022-12-06
JP2019031509A (ja) 2019-02-28
JP2016504290A (ja) 2016-02-12
KR20220016305A (ko) 2022-02-08
CA2892045A1 (en) 2014-05-30
CU24387B1 (es) 2019-03-04
EP2922828A2 (en) 2015-09-30
ECSP15019948A (es) 2016-01-29
CL2015001377A1 (es) 2016-02-19
SG10201600149VA (en) 2016-02-26
IL265253A (en) 2019-05-30

Similar Documents

Publication Publication Date Title
US11180483B2 (en) Substituted reverse pyrimidine Bmi-1 inhibitors
US10370371B2 (en) Substituted pyrimidine Bmi-1 inhibitors
US10584115B2 (en) Substituted pyridine and pyrazine BMI-1 inhibitors
US9975878B2 (en) Substituted triazine BMI-1 inhibitors
BR112016004511B1 (pt) Composto, composto ou uma forma do mesmo, uso de um composto ou forma do mesmo, e composição farmacêutica para uso no tratamento de um câncer mediado por bmi-1

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000